What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...

The stock market has recently witnessed significant movements among key players in the technology and healthcare sectors.

Eli Lilly’s stock has hit a 52-week low at $697.35, nosediving over 10% this past week, which has investors holding their ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Shares of technology tumbled with Apple Inc. leading the charge lower. That decline came on the heels of President Donald ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...